Medicus Pharma Ltd (MDCX)

$0.32 -0.02 (-5.26%)
Market Cap 13.91M
Revenue (ttm) 0.00
Net Income (ttm) -35.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 925,300
Avg Vol 7,885,028
Day's Range N/A - N/A
Shares Out 41.82M
Stochastic %K 60%
Beta -0.47
Analysts Strong Sell
Price Target $6.50

Company Profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus P...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 610 636 0184
Address:
300 Conshohocken State Road, Suite 200, West Conshohocken, United States
bertito
bertito May. 13 at 12:45 PM
$MDCX im in... 7k shares! lets get this party started!!!
0 · Reply
Macarther
Macarther May. 12 at 4:45 PM
$MDCX This month full of upcoming news 🤌
1 · Reply
Sum_guy_69
Sum_guy_69 May. 12 at 11:38 AM
$MDCX Have a good start to your day
0 · Reply
Gainermaxim
Gainermaxim May. 11 at 9:52 AM
$MDCX When FDA approval?
1 · Reply
Cullousus
Cullousus May. 10 at 3:18 AM
$MDCX consolidation leads to a run..
0 · Reply
WuTangMane
WuTangMane May. 8 at 8:17 PM
$MDCX
0 · Reply
Macarther
Macarther May. 8 at 8:11 PM
$MDCX big news come from FDA
0 · Reply
Girldadt
Girldadt May. 8 at 7:50 PM
$MDCX boom
0 · Reply
Girldadt
Girldadt May. 8 at 7:45 PM
$MDCX looking good lets go
0 · Reply
mental_illness_patient
mental_illness_patient May. 8 at 7:29 PM
$MDCX pamp et
0 · Reply
Latest News on MDCX
Medicus Pharma announces results from Phase 2 SKNJCT-003 analysis

2026-05-07T03:48:38.000Z - 6 days ago

Medicus Pharma announces results from Phase 2 SKNJCT-003 analysis

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

May 6, 2026, 7:30 AM EDT - 7 days ago

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma meets with lawmakers to support SkinJect designations

2026-04-27T13:31:02.000Z - 15 days ago

Medicus Pharma meets with lawmakers to support SkinJect designations

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Apr 27, 2026, 7:30 AM EDT - 16 days ago

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma initiated with a Buy at Roth Capital

2026-04-21T11:53:55.000Z - 22 days ago

Medicus Pharma initiated with a Buy at Roth Capital

Medicus Pharma submits ODD application to U.S. FDA for SkinJect

2026-04-17T11:35:50.000Z - 26 days ago

Medicus Pharma submits ODD application to U.S. FDA for SkinJect

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Apr 17, 2026, 7:30 AM EDT - 26 days ago

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

Apr 15, 2026, 7:30 AM EDT - 4 weeks ago

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

Medicus Pharma enters media partnership with New to The Street

2026-04-07T14:23:02.000Z - 5 weeks ago

Medicus Pharma enters media partnership with New to The Street

Medicus Pharma submits clinical study design to FDA for Teverelix

2026-04-06T11:37:11.000Z - 5 weeks ago

Medicus Pharma submits clinical study design to FDA for Teverelix

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Apr 6, 2026, 7:30 AM EDT - 5 weeks ago

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Apr 1, 2026, 7:30 AM EDT - 6 weeks ago

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Medicus Pharma reports principal investigator validation of Phase 2 data

2026-03-30T13:38:08.000Z - 6 weeks ago

Medicus Pharma reports principal investigator validation of Phase 2 data

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Mar 30, 2026, 7:30 AM EDT - 6 weeks ago

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Mar 26, 2026, 7:30 AM EDT - 6 weeks ago

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

Mar 25, 2026, 4:30 PM EDT - 6 weeks ago

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

Medicus Pharma to discuss Skinject Phase 2 reults in fireside chat

2026-03-18T11:52:25.000Z - 2 months ago

Medicus Pharma to discuss Skinject Phase 2 reults in fireside chat

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

Mar 18, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

Medicus Pharma announces SkinJect Phase 2 KOL update

2026-03-16T11:50:31.000Z - 2 months ago

Medicus Pharma announces SkinJect Phase 2 KOL update

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Mar 16, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

Mar 10, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

Medicus Pharma provides interpretation of Phase 2 SkinJect dataset

2026-03-09T11:40:33.000Z - 2 months ago

Medicus Pharma provides interpretation of Phase 2 SkinJect dataset

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Mar 9, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Medicus Pharma announces results from Phase 2 study of D-MNA

2026-03-05T13:10:22.000Z - 2 months ago

Medicus Pharma announces results from Phase 2 study of D-MNA

Medicus Pharma announces results from Phase 2 study of D-MNA

2026-03-05T12:35:46.000Z - 2 months ago

Medicus Pharma announces results from Phase 2 study of D-MNA

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Mar 5, 2026, 7:30 AM EST - 2 months ago

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Medicus Pharma To Participate in the 38th Annual Roth Conference

Mar 3, 2026, 7:30 AM EST - 2 months ago

Medicus Pharma To Participate in the 38th Annual Roth Conference

Medicus Pharma on Bloomberg World

Feb 12, 2026, 7:30 AM EST - 3 months ago

Medicus Pharma on Bloomberg World

Medicus signs six-part media series with New to the Street

2026-02-10T13:40:50.000Z - 3 months ago

Medicus signs six-part media series with New to the Street

Medicus receives FDA ‘study may proceed’ clearance for Teverelix Phase 2b study

2026-02-10T12:35:27.000Z - 3 months ago

Medicus receives FDA ‘study may proceed’ clearance for Teverelix Phase 2b study

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Feb 10, 2026, 7:30 AM EST - 3 months ago

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Jan 23, 2026, 7:30 AM EST - 3 months ago

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Medicus announces amendment to LifeArc license improving Teverelix profile

2026-01-22T12:35:45.000Z - 3 months ago

Medicus announces amendment to LifeArc license improving Teverelix profile

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Jan 22, 2026, 7:30 AM EST - 3 months ago

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

Jan 20, 2026, 7:30 AM EST - 4 months ago

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

Medicus Pharma announces clinical data on Teverelix

2026-01-12T12:50:08.000Z - 4 months ago

Medicus Pharma announces clinical data on Teverelix

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Jan 12, 2026, 7:30 AM EST - 4 months ago

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Jan 5, 2026, 7:30 AM EST - 4 months ago

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Medicus Pharma enters non-binding LOI with Reliant AI

2025-12-22T12:46:17.000Z - 5 months ago

Medicus Pharma enters non-binding LOI with Reliant AI

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Dec 22, 2025, 7:30 AM EST - 5 months ago

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Medicus Pharma completes enrollment of 90 patients for Phase 2 study

2025-12-15T12:47:00.000Z - 5 months ago

Medicus Pharma completes enrollment of 90 patients for Phase 2 study

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Dec 15, 2025, 7:30 AM EST - 5 months ago

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Dec 5, 2025, 3:20 PM EST - 5 months ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Dec 1, 2025, 8:00 AM EST - 5 months ago

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Medicus Pharma appoints Carolyn Bonner as CFO

2025-12-01T12:35:47.000Z - 5 months ago

Medicus Pharma appoints Carolyn Bonner as CFO

Medicus Pharma explores novel treatment innovations for prostate, skin cancers

2025-11-24T13:15:38.000Z - 6 months ago

Medicus Pharma explores novel treatment innovations for prostate, skin cancers

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Nov 24, 2025, 8:00 AM EST - 6 months ago

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 17, 2025, 7:30 AM EST - 6 months ago

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Nov 14, 2025, 5:00 PM EST - 6 months ago

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 13, 2025, 7:30 AM EST - 6 months ago

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 22, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Oct 14, 2025, 8:07 AM EDT - 7 months ago

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Oct 13, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Oct 7, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Sep 29, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Sep 24, 2025, 9:26 AM EDT - 8 months ago

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Sep 24, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Sep 18, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Sep 8, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Sep 2, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Aug 21, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Aug 4, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Jul 23, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Jul 21, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Jul 8, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Jun 30, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Jun 23, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Medicus Pharma Ltd. to Present at 2025 Bio International Convention

Jun 12, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Ltd. to Present at 2025 Bio International Convention

bertito
bertito May. 13 at 12:45 PM
$MDCX im in... 7k shares! lets get this party started!!!
0 · Reply
Macarther
Macarther May. 12 at 4:45 PM
$MDCX This month full of upcoming news 🤌
1 · Reply
Sum_guy_69
Sum_guy_69 May. 12 at 11:38 AM
$MDCX Have a good start to your day
0 · Reply
Gainermaxim
Gainermaxim May. 11 at 9:52 AM
$MDCX When FDA approval?
1 · Reply
Cullousus
Cullousus May. 10 at 3:18 AM
$MDCX consolidation leads to a run..
0 · Reply
WuTangMane
WuTangMane May. 8 at 8:17 PM
$MDCX
0 · Reply
Macarther
Macarther May. 8 at 8:11 PM
$MDCX big news come from FDA
0 · Reply
Girldadt
Girldadt May. 8 at 7:50 PM
$MDCX boom
0 · Reply
Girldadt
Girldadt May. 8 at 7:45 PM
$MDCX looking good lets go
0 · Reply
mental_illness_patient
mental_illness_patient May. 8 at 7:29 PM
$MDCX pamp et
0 · Reply
mental_illness_patient
mental_illness_patient May. 8 at 6:35 PM
$MDCX heck yea im up 20 percent now
0 · Reply
WuTangMane
WuTangMane May. 8 at 6:14 PM
$MDCX boom
0 · Reply
Cullousus
Cullousus May. 8 at 5:32 PM
$MDCX
1 · Reply
WuTangMane
WuTangMane May. 8 at 3:02 PM
$YMAT $MDCX $GCTK
0 · Reply
WuTangMane
WuTangMane May. 8 at 12:11 PM
$MDCX consolidation and uptrend this afternoon into weekend
0 · Reply
Fire_Truck
Fire_Truck May. 7 at 5:38 PM
$MDCX They have till October 19 to regain compliance. I'll wait untill all the termoil to start before an entry. Probably right before the actual R/S date to be announced.
1 · Reply
hughbeefman69
hughbeefman69 May. 7 at 1:45 PM
$MDCX lotssss of buying this early before volume, you love to see it
0 · Reply
Cullousus
Cullousus May. 7 at 1:38 PM
$MDCX
1 · Reply
Cullousus
Cullousus May. 7 at 12:20 PM
$MDCX
0 · Reply
Sum_guy_69
Sum_guy_69 May. 7 at 5:32 AM
$MDCX Good Vibes Here
0 · Reply
razorsedge4343
razorsedge4343 May. 7 at 1:51 AM
$MDCX if they run a few more commercials on CNBC maybe we'll finally get over 50 cents a share! 😂🤦
0 · Reply